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Abstract
Updated models of the Rat Cytochrome P450 2D enzymes are produced based on the recent x-ray structures of the Human
P450 2D6 enzyme both with and without a ligand bound. The differences in species selectivity between the epimers quinine
and quinidine are rationalised using these models and the results are discussed with regard to previous studies. A close
approach to the heme is not observed in this study. The x-ray structure of the enzyme with a ligand bound is shown to be a
better model for explaining the observed experimental binding of quinine and quinidine. Hence models with larger closed
binding sites are recommended for comparative docking studies. This is consistent with molecular recognition in
Cytochrome P450 enzymes being the result of a number of non-specific interactions in a large binding site.
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Introduction
Human cytochrome P450 2D6 (CYP2D6), part of the
cytochrome P450 (CYP450) superfamily of heme containing
enzymes, plays an important role in the phase I mono-oxygenase
metabolism of xenobiotic substrates being responsible for the
metabolism of <20% of therapeutic drugs in current clinical use
[1].
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The importance of CYP450s to drug metabolism has long made
them a target for investigation e.g. oxidation by CYP450s can
activate prodrugs to their therapeutically active form, while their
wide substrate specificity can result in drug-drug interactions, often
detrimental to patient health. This is particularly obvious in the
case of the CYP2D family, which due to its highly polymorphic
nature can have a great deal of variability in terms of its
metabolism. Better understanding of the molecular determinants
of reactivity and specificity is therefore required.
Traditionally, animal models are used to predict a drug’s
ADME-Tox properties, with the rat being one of the most
common animal models used. However, there are questions
regarding the transferability of these models to Human. Rats, after
all, have 6 CYP2D enzymes; CYP2D1-2D5 and CYP2D18,
compared to only one in humans, CYP2D6. The rat and human
CYP2D isoforms show a reasonably high sequence identity overall
(<56%) but this is significantly lower in the active site region
(<34%).
A key example of this is the observed species difference is the
effect of chirality on CYP2D6. The chiral enantiomers of
quinidine and quinine show a species selective response when
metabolised by either human or rat (Figure 1). Quinidine is
observed to be a strong inhibitor of human CYP2D6, while
quinine, although having no effect on human CYP2D6 metabo-
lism is a strong inhibitor of rat CYP2D enzymes, especially rat
CYP2D2 (Table 1 and Table 2).
Previous modelling work on Cytochrome P450 has been carried
out by Lewis, see for example [2] and references therein. Recently
Zhang has published a machine learning model of species
selectivity [3] which has a greater than 80% accuracy in predicting
selectivity. However, models of this kind do not provide
information on the three dimensional structure of the active sites
of the proteins nor the interactions made by the ligands. Similarly,
there have been many studies that have used quantitative structure
activity relationships [2] to probe ligand binding but again these
studies lack 3 dimensional information. Mulholland et al. [4] have
used the combined techniques of QM/MM to study the
interactions with the iron in CYP, which is the currently highest
level of modelling that can be achieved in proteins and have been
useful in describing the mechanistic details of the catalytic cycle.
Venhorst et al. [1] have generated homology models based on the
x-ray structure of rabbit CYP2C5 and used this to identify 22
active site residues that are of importance in ligand binding. In this
work we have based our models on the now available x-ray
structures of the Human CYP2D6 which is a better starting point
for the comparison. Computational techniques, such as homology
modelling and molecular docking can be used to effectively
investigate any sequence variation between species. This work
describes a variety of techniques used to create homology models
of rat CYP2D and to investigate the cause of species selectivity in
Rat and Human enzymes.
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Previous work on molecular recognition in antibody:antigen
interactions concluded that the ability of antibodies to recognise a
wide variety of ligands was not due to specific interactions with
certain key selected amino acids but rather was due to a range of
non-specific interactions in the overall active site [5]. CYP450’s
also show this inducible nature where they can also respond to a
wide variety of ligands and one of our aims in this paper was to see
if, with ligands that differ only in the arrangement about one chiral
centre, quinidine and quinine would show specific interactions or
would also show non-specific binding.
Methodology
Homology Models of Rat Cytochrome P450 2D Enzymes
Full length sequences of human and rat CYPs were taken from
the UniProt database [6] with a combination of PSIPred [7], JPred
[8] and Porter [9] being used to predict the secondary structure of
the rat CYPs. A series of sequence alignments were generated
using ClustalX [10,11] based on all known human and rat CYP2D
sequences (Figure 2). The predicted secondary structure from
PSIpred, JPred and Porter disagreed at one point with that
predicted from ClustalX. Hence a manual modification of the
sequence alignment was performed to give the best consensus
match with the highest sequence identity (<57% between all rat
CYP2D enzymes and <56% between rat and human CYP2D
enzymes). The Molecular Operating Environment (MOE) [12]
was then used to generate 25 high-precision, three-dimensional
homology models for rat cytochrome P450 2D1–5 and 2D18
enzymes. The models were based on the available human
CYP2D6 crystal structures both with a ligand bound in the active
site (PDB entry code 3QM4 [13]) and without (PDB entry code
2F9Q [14]). Models were generated under both the Amber99 and
Charmm27 force fields and all relevant crystallographic informa-
tion was retained. The models formed were analysed both visually
and statistically within MOE [12].
Molecular Dynamics Studies on Homology Models
MOE [12] was used to perform a series of molecular dynamics
(MD) simulations in vacuo to judge the stability and quality of the
homology models generated. The simulations were performed
using the NPT ensemble, which holds the number of atoms, the
pressure and the temperature constant throughout the simulation
while allowing volume to vary. This ensemble was chosen as the
simulations were performed at body temperature and pressure
which is not normally subject to change in biological systems.
Simulations were run at both 0 K and 0 Pa for 2 ps and 310 K
and 101 Pa for 2 ps.
CYP2D Active Site Studies
Site Finder [15] available within MOE [12] was used to
generate a series of possible ligand binding sites within the two
human CYP2D6 crystal structures, by identifying clusters of
relevant ‘alpha spheres’ considered to be in solvent accessible
regions of hydrophobicity and hydrophilicity [16,17]. A surface
analysis of the active sites of both human CYP2D6 crystal
structures was performed using the surface mapping tool available
within MOE [18,19,20] with the active site definitions being taken
from literature [1] and the Site Finder [15] analysis.
Inhibitor Docking
Quinidine and quinine, which are known inhibitors of human
Cytochrome P450 2D6 were docked into both the human
CYP2D6 crystal structures [13,14] and the rat CYP2D homology
models using the available MOE docking program. In previous
work from our group [21] results more consistent with experiment
have been achieved by docking the x-ray crystal structure of the
ligand rather than a model built up on an atom by atom basis.
Therefore we have docked both the x-ray crystal structure of
quinidine [22] and the molecular model of quinidine and the
model of quinine as there is no x-ray structure of quinine available.
Docking was performed using three methods; an alpha triangle
rigid-protein-flexible-ligand dock with a force field based refine-
ment step and London DG scoring functions, an alpha triangle
rigid-protein-rigid-ligand dock with a Gridmin based refinement
step and London DG scoring function and a manual placement
and force field based minimisation step. As the force field based
methods caused some anomalies to occur with the aromatic rings
Figure 1. Structures of the epimers quinine and quinidine.
doi:10.1371/journal.pone.0063335.g001
Table 1. Experimental IC50 values for quinidine and quinine
in rat and human CYP2D taken from Venhorst et al. [1].
IC50/mM
Ligand CYP2D1 CYP2D2 CYP2D3 CYP2D4 CYP2D6
Quinidine 19.961.9 2.860.7 26.964.4 47.2613.4 0.003360.001
Quinine 46.567.6 0.009460.009 12.060.2 1.760.4 0.6160.05
doi:10.1371/journal.pone.0063335.t001
Species Selectivity in Cytochrome P450 2D6
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Figure 2. Sequence Alignment of Human CYP2D6 and all Rat CYP2D enzymes. a-helices are shown in red, b-sheets in yellow and b-turns in
blue. The sequence alignment was generated using both ClustalX and the MOE sequence alignment program.
doi:10.1371/journal.pone.0063335.g002
Species Selectivity in Cytochrome P450 2D6
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of the ligands, the Gridmin based docking method was used as this
greatly reduced the number of observed anomalies in this case.
The manual placement method was used to see if interaction with
the Fe atom was possible with these ligands. In practice as these
ligands are inhibitors and not substrates the Gridmin results were
taken as less subject to bias on our behalf and none of these
dockings showed a close approach to the Fe atom. The difference
in docking behaviour between substrates and inhibitors will be the
subject of the further publication.
For each of the docks, the following information was recorded
for each contact made with the protein (more than one in some
cases):
N Residue types, number and subunit
N Bonding type (backbone acceptor/donor, H-bond acceptor/
donor (side chain));
N Distance between donor and acceptor as calculated by MOE
(A˚);
N Contact point on the ligand according to the numbering
scheme.
Table 2. Experimental and Calculated Ki values for quinidine
and quinine in both crystal structures of human CYP2D6.
Ligand
Experimental
Ki/mM
Calculated
Ki/mM
Quinidine Crystal Structure 0.03 2.1361027 (2F9Q)
5.0761029 (3QM4)
Quinidine Molecular Structure 0.03 2.6561028 (2F9Q)
2.0161028 (3QM4)
Quinine 5.9 1.4161026 (2F9Q)
2.7761027 (3QM4)
doi:10.1371/journal.pone.0063335.t002
Figure 3. Ramachandran Plot for a model of rat CYP2D1 based
on 2F9Q.
doi:10.1371/journal.pone.0063335.g003
Figure 4. Quinidine inducibly docked into a model of human CYP2D6 based on the 2F9Q crystal structure. Quinidine is shown in
orange inside the active site which is shown in green.
doi:10.1371/journal.pone.0063335.g004
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PLOS ONE | www.plosone.org 4 May 2013 | Volume 8 | Issue 5 | e63335
Ligand Optimisation
In order to correct for the anomalies in aromatic structure
observed during docking, a ligand optimisation script provided by
MOE [12] was employed. This script duplicated the docked ligand
and corrected the confirmation before refining the duplicate on to
the original confirmation. This step was only required for the
docks of quinidine and quinine in the 2F9Q based models of
CYP2D2 and for quinidine in CYP2D5. No such anomalies were
observed when docking to the 3QM4 based structures.
Protein-Ligand Binding Analysis
A combination of the 3D ligand interaction prediction and 2D
ligand interaction tool from MOE were used to predict and
visualise protein-ligand interactions likely to occur for each of the
bioactive compounds docked.
Induced Docking Model
Owing to the inducible nature of CYP2D enzymes a further
energy minimisation step was introduced into the docking analysis
in order to more accurately model enzyme response. After docking
the protein was minimised under the CHARMM27 force field
[23] which is parameterised for protein simulations around the
fixed heme and docked ligand providing a representation of the
induced docking model.
Calculation of Ki from DG
Ki values were calculated for each of the docked compounds for
comparison with experimental values (Table 1 and Table 2). Ki
values were calculated from DG using;
DG~{RT lnKeq ð2Þ
Keq~
1
Ki
ð3Þ
DG~{RT ln
1
Ki
ð4Þ
DG~RT lnKi ð5Þ
Ki~e
DG
RT ð6Þ
Figure 5. Quinidine inducibly docked into a model of human CYP2D6 based on the 3QM4 crystal structure. Quinidine is shown in
orange inside the active site which is shown in green.
doi:10.1371/journal.pone.0063335.g005
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Results and Discussion
The homology models were analysed by Ramachandran plots
(Figure 3). This clearly shows that 99% of the residues are in
allowed conformations and there are no outliers, providing
confidence in the models used. The x-ray structure of prinomastat
bound to Cytochrome P450 2D6 [14] was used to validate the
docking procedure. The docking results showed that MOE was
able to reproduce the x-ray structure with an rmsd of 0.5592 A˚
and that prinomastat was in the vicinity of Ser304 and Glu219.
There is no interaction in this x-ray structure with Asp301, which
has been proposed as a vital residue [24]. One of the major
concerns in cytochrome P450 modelling is the inducibility of the
active site [25] i.e. if one compares the x-ray structures of the
native Human 2D6 with the structure with prinomastat bound
there is a significant difference (increase in volume of 130 A˚) in the
active sites. The active site of the ligand bound structure is larger
but more closed indicating that the protein has conformed to the
shape of the ligand. Therefore we have carried out docking to both
the homology models of the native enzyme and the ligand bound
models (Figures 4 and 5). Table 3 shows that there are more
interactions with amino acid residues in all models for those based
on 2F9Q rather than 3QM4 indicating that the active site is
smaller as discussed above. Table 3 shows the close approaches
(within 3.8 A˚) of amino acid residues in the rat and human models
(based on 2F9Q and 3QM4) with both quinine and quinidine.
Figure 6 shows a visual representation of the interactions
summarised in Table 3, which makes the data presented easier
to interpret. In the models based on the 2F9Q structure
interactions with residue 304 occur for all rat and human models
for both ligands. Residue 213, 216, 244 and 301 are shown to
interact with both human and rat models in quinidine but not in
quinine, whereas quinine interacts with 308, 374 and 483 in both
human and rat but not in quinidine. Interactions that occur in
both human and rat models indicate similar modes of binding in
both models. There are ten interactions with the Human 2D6
model in quinidine but only seven in quinine. Of these only four
are common, i.e. those with 217, 220, 304 and 373. In the models
based on 3QM4, residues 216, 244, 301, 304 and 309 show
interactions with both ligands in both human and rat structures
with almost all rat and human models showing interactions with
301 for both ligands. There are ten observed interactions with
quinidine and nine with quinine in the human structure. Of these
interactions seven are common including residues 117, 216, 244,
301, 304, 309 and 484. Previous work on the docking of quinine
and quinidine using the models based on the rabbit x-ray structure
[1] indicated the quinidine interacted with Asp301, Ser304 and
Phe120 in the human model and couldn’t approach Asp301 as
Figure 6. Interaction diagram showing an overlay of quinidine (green) and quinine (orange) in a) Human 2D6 (2F9Q), b) Rat 2D2
(2F9Q), c) Human 2D6 (3QM4), d) Rat 2D2 (3QM4). The lines shown in green are electrostatic interactions (pi bonding or H bonding).
doi:10.1371/journal.pone.0063335.g006
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closely in the Rat 2D2 model but formed a hydrogen bond to the
main chain of Met304 (replaces Ser304 in 2D2). In this work,
interactions between 2D2 and Asp301 are found with models
based on 2F9Q showing a movement of the Met304 side chain
during the energy minimisation step to allow for interaction
between quinidine and Asp301. For those models based on 3QM4
the Met304 side chain is already in a position which allows for
interaction with Asp301. In the previous work on the quinine
docking [1], interactions were found to the carbonyl backbone of
301 in the human model and to Asp216, Thr217 and Met304 in
the rat 2D2 model. Interactions were found to backbone and side
chain of Asp301 in the 3QM4 and 2F9Q human structures
respectively, but neither Asp216 nor Met304 interactions were
observed for rat 2D2.Experimental binding data for Human 2D6
(Table 1 and Table 2) shows quinine binds approximately 1000
times less well than quinidine. In both the 2F9Q and 3QM4 based
models of human 2D6, more interactions were observed for
quinidine than quinine. However, the experimental binding
situation is reversed in the Rat 2D2 where quinine binds
approximately 1000 times tighter than quinidine. Here the
quinine should make more contacts with the protein. This is seen
in the 3QM4 model where ten contacts are observed for quinine
while quinidine has only nine. In fact these results follow the
experimental data in most cases with more interactions being
observed for the more potent epimer for all but the 2F9Q based
model of 2D2 and the 3QM4 based model of 2D1. If the lowest
energy docking results are considered (Table 4), in the models
based on the 2F9Q structure for the 2D2 case the quinine has a
lower free energy of binding than the quinidine model structure,
211.68 to 29.8 Kcal/mol. The results are reversed when the
Table 3. Amino acid residue interactions with Quinidine and Quinine in models based on both crystal structures.
Ligand 2F9Q 3QM4
Residue
Number Quinidine Quinine Quinidine Quinine
54 2D18
107 2D2, 2D3 (p) 2D2 (p)
110 2D2
112 2D2, 2D3 2D2
117 2D6, 2D6 (p) 2D6 (p)
120 2D6 2D1 (p), 2D2 (p) 2D1, 2D4, 2D4 (p), 2D18, 2D18 (p)
121 2D3, 2D4 2D18 2D2 2D2, 2D3, 2D18
208 2D6
209 2D6
212 2D3
213 2D2, 2D3 (p), 2D6, 2D18 2D1, 2D3, 2D4, 2D5, 2D5 (p) 2D3
216 2D2, 2D3, 2D6 2D1, 2D2, 2D3 2D1, 2D2, 2D4, 2D5, 2D6, 2D18 2D2, 2D4, 2D5, 2D6, 2D18
217 2D2, 2D3, 2D4, 2D6 2D3, 2D5, 2D6, 2D18
220 2D2, 2D3, 2D4, 2D6, 2D18 2D2, 2D6, 2D18, 2D18 (p)
244 2D1, 2D5, 2D6 2D3 2D1, 2D3, 2D6 2D1, 2D2, 2D5, 2D6, 2D18
248 2D2
297 2D2, 2D4 2D3, 2D4
300 2D6 2D3 2D1, 2D4, 2D18 2D1, 2D2, 2D3, 2D4, 2D5, 2D6, 2D18
301 2D1, 2D2, 2D6 2D1, 2D2, 2D3 2D1, 2D2, 2D3, 2D4, 2D5, 2D6, 2D18 2D1, 2D3, 2D4, 2D5, 2D6, 2D18
304 2D1, 2D2, 2D3, 2D4, 2D5,
2D6, 2D18
2D1, 2D2, 2D3, 2D4, 2D5, 2D6,
2D18
2D2, 2D4, 2D6, 2D18 2D1, 2D2, 2D4, 2D6, 2D18
305 2D3, 2D4, 2D18 2D2, 2D3, 2D18 2D2, 2D4 2D1, 2D2, 2D3, 2D4, 2D18
308 2D2, 2D18 2D3, 2D5, 2D6, 2D18 2D18 2D6
309 2D1, 2D2, 2D3 2D1, 2D3, 2D4 2D1, 2D5, 2D6 2D3, 2D6
369 2D1
370 2D2, 2D18 2D2, 2D4 2D3, 2D5
372 2D18 2D4, 2D18
373 2D1, 2D2, 2D4, 2D5,
2D6, 2D18
2D1, 2D4, 2D6, 2D18 2D5, 2D18 2D1, 2D3, 2D18
374 2D1, 2D1 (p), 2D2, 2D3, 2D18 2D2, 2D3, 2D6, 2D18 (p) 2D1, 2D5
375 2D4
482 2D18
483 2D3, 2D4, 2D5, 2D18 2D1, 2D4, 2D5, 2D6, 2D18 2D5 2D1, 2D2 (p), 2D18
484 2D1, 2D5, 2D18 (p) 2D3, 2D4, 2D5 2D6, 2D18 2D6
doi:10.1371/journal.pone.0063335.t003
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quinidine x-ray structure is compared to the quinine model
structure, indicating that there is no advantage in using the x-ray
structure in this case. In the 2D6 model based on 2F9Q, it is the
quinidine model that has the lowest binding free energy. This is
consistent with the experimental results. For the models based on
the 3QM4 structure the quinidine (X-ray or model structure) has a
lower free energy of binding than the quinine in all cases. This is
only consistent with experiment for the 2D6 case, so these results
cannot explain the difference observed in the 2D2 case. Therefore,
in the case of simulated binding free energies, the models based on
the open active site are more consistent with experiment. In the
previous work [1], the differences in binding efficiency between
the epimers were ascribed to the difference in close approach to
the iron atom in the heme. However, it was stated that the ligands
were located close to the heme in this work but that this was not a
requirement for all competitive inhibitors, like these ligands, and
multiple binding modes are possible. These large differences in
experimental binding efficiency cannot be prescribed wholly to
small differences in interaction energies, so as in the antibody:anti-
gen case, it is the sum total of the weak interactions overall that
account for the inducible nature of CYP450 binding and this is
true in the qunine:quinidine case also. The large non-specific
binding site of CYP450 is ideally suited to binding a wide variety
of ligands.
In ligands with polar groups prominent there is an interaction
observed with the iron of the Heme in the protein. This is
consistent with the x-ray results for prinomastat which shows a Fe-
N interaction with the pyridinyl ring. However, we do not observe
a close approach to the iron in our docking studies. This may
suggest that as both quinine and quinidine are inhibitors (at least
in vitro [26]), their roles are to occupy space in the binding site
thereby denying other ligands access to the active site.
Conclusions
The basis of species selectivity in human and rat cytochromes is
a complex problem, which demonstrates clearly how non-specific
binding can be used in nature to ‘engineer’ proteins that are able
to bind to a wide variety of substrates. An induced fit minimisation
step is shown to be useful in reproducing experimental docking
results. Hence models based on the larger closed active site in the
3QM4 structure are better models of the observed experimental
data for quinidine and quinine than those based on the more open
2F9Q and that there are differences in both the number of
interactions made by different ligands as well as their close
approaches and it is important to take this into account when
seeking to understand their binding. In all of the rat models
studied this is true apart from 2D1 where the 2F9Q model is better
at reproducing the experimental binding data.
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